Form 4: Inozyme Pharma CEO Douglas Treco Reports Stock Transactions
SEC Form 4 Filing
CEO Douglas Treco of Inozyme Pharma reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On April 1, 2025, Douglas Treco, CEO and Chairman of Inozyme Pharma, settled 25,000 restricted stock units (RSUs) into common stock.
- Following this transaction, Treco directly owns 49,865 shares of common stock, including 2,490 shares acquired through the Employee Stock Purchase Plan on March 31, 2025.
- On April 2, 2025, Treco sold 8,819 shares at $0.89 per share to cover tax withholding obligations related to the RSU vesting, leaving him with 41,046 shares.
- The sale was executed automatically under a pre-arranged instruction letter and does not represent a discretionary trade.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding insider transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's stock ownership.
Key Dates
| Date | Description |
|---|---|
| 04/01/2023 | Reporting person was granted 100,000 RSUs which vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. |
| 03/31/2025 | 2,490 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan. |
| 04/01/2025 | Settlement of 25,000 Restricted Stock Units (RSUs). |
| 04/02/2025 | Sale of 8,819 shares at $0.89 per share to cover tax obligations. |
| 04/03/2025 | Date of Form 4 filing. |
Keywords
Form 4, Inozyme Pharma, Douglas Treco, RSU, Stock Sale, Beneficial Ownership, INZY
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.